Blood Pressure Management in IPH and SAH with EVD

Primary Causes of Blood Pressure Variability

Cerebral autoregulation impairment is associated with poor outcomes and causes fluctuations in blood pressure in patients with SAH and IPH, as the brain attempts to maintain adequate cerebral perfusion 1, 2
EVD-related pressure changes alter cerebrospinal fluid dynamics, causing significant variations in intracranial pressure and affecting blood pressure as the body attempts to maintain cerebral perfusion pressure 3, 4

Increased CSF drainage through the EVD correlates with increasing PaCO2 levels, altering cerebral blood flow and affecting blood pressure in patients with SAH and IPH 3
Rapid changes in ICP triggered by CSF drainage through the EVD cause compensatory blood pressure responses 4

The American Heart Association recommends maintaining blood pressure in the normotensive range (SBP <160 mmHg) during the pre-aneurysm securing phase to reduce rebleeding risk in patients with SAH and IPH 5
The American Stroke Association suggests that blood pressure targets shift dramatically during the post-aneurysm securing phase, often requiring induced hypertension (MAP >90 mmHg) to prevent delayed cerebral ischemia in patients with SAH and IPH 5

Vasopressors used for induced hypertension to treat symptomatic vasospasm can cause fluctuations in blood pressure readings in patients with SAH and IPH 7, 1

The American College of Cardiology recommends arterial line monitoring over non-invasive cuff monitoring for SAH patients due to the need for precise, continuous monitoring 6
Cerebral perfusion pressure targets should be maintained between 50-70 mmHg, depending on the status of cerebral autoregulation, which may require adjusting blood pressure targets in patients with SAH and IPH 4

Continuous arterial blood pressure monitoring is essential for precise management in patients with SAH and IPH with EVD, according to the American Heart Association 6
Avoiding rapid BP fluctuations is crucial, as they are associated with increased rebleeding risk and may worsen outcomes in patients with SAH and IPH 1, 6
Coordinating EVD management with blood pressure control is necessary, as changes in one will affect the other in patients with SAH and IPH 3, 4
Monitoring for signs of vasospasm (days 4-14 after SAH) is essential, which may require induced hypertension and can cause variable blood pressure readings in patients with SAH and IPH 7, 2